The meta-analyses that have attempted to evaluate the efficacy of ibandronate in the prevention of non-vertebral fractures present conflicts of interest and problems of grouping different doses, indirect comparisons, incorrect analysis and modifications in populations. It has not been demonstrated that ibandronate at habitual doses is effective. The  conclusions of the authors are excessively favourable, and consequently this has been magnified in the practical guidelines.